Current QIMR Berghofer appointment
- 1995 – current: Group Leader, Inflammation Biology
Other current appointments
- 2014 – current: Adjunct Professor, University of Queensland
- 2011 – current: Adjunct Professor, Griffith University
- 2014 – current: Adjunct Professor. James Cook University
- 2009 – current: NHMRC Principal Research Fellow
- 2000 – 2014: Adjunct Associate Professor, University of Queensland
- 1986 – 1989: Research Officer, Imperial College of Science and Technology, United Kingdom
- 1990 – 1995: Wellcome Trust Training Fellowship, UK. Royal Society Fellowship
CURRENT AREAS OF RESEARCH
The Inflammation Biology Group uses mouse models of inflammation, primarily arboviral disease models, to gain new insights into immunopathologies and to test and develop new interventions. The group collaborates extensively with industry partners to help develop new interventions for human diseases. This includes pre-clinical R&D, generating data for patents, non-human primate studies and early human studies.
Professor Suhrbier’s complete list of publications can be viewed at his Google Scholar page.
COMMERCIAL AND TRANSLATION ACTIVITIES
The Inflammation Biology Group has undertaken industry funded collaborative R&D with Australian Biotech (e.g. Sementis, Peplin) and international Pharma (e.g. GSK, Valneva, Abbivax, Leo Pharma). In the last 5 years Dr. Suhrbier has been a consultant for Leo Pharma, WHO, GSK, ABIVAX, Valneva, and Paradigm. Andreas is an unpaid member of the Scientific Advisory Board of Sementis. Past consultancies include Bavarian Nordic, CSL, Replikun and Aventis.
Andreas is an inventor on 17 international patents; 13 of these have been commercialised, 11 cover products that reached human testing, and 7 cover Picato, a pro-inflammatory approved topical treatment for actinic keratoses (precursors of skin cancer).
According to PatCite (Patent Citation Index) 65 of Andreas’s papers are cited in 554 patent documents/346 patent families; this represents 37% of Andreas’s research publications.
- We have recently established a key role for granzyme A in driving the arthritic pathology seen after infection with chikungunya virus and Ross River virus. Granzyme A represents a potential new therapeutic target for drug development to prevent inflammation and associated pain.
- We have established that Ross River virus and chikungunya virus arthropathy usually affects the joints in the extremities (e.g. arms, legs, hands, feet) simply because they are a little cooler than the core temperature of 37°C. A reduction of temperature by only a few degrees severely compromises the antiviral interferon system, thereby increasing viral replication.
- We have used newly established mouse models of Zika virus fetal brain infection and testes damage to illustrate the efficacy of a new vaccine against Zika virus in collaboration with Sementis Ltd.
- 2014: NHMRC External Project Grant Assessor Outstanding Contribution Honour Roll. (84 named nationally, 2 named within QIMR B)
- 2010: Eureka Award Finalist. Category: Medical Research Translation (The Industry & Investment NSW Jamie Callachor Eureka Prize). A new anti-cancer drug from radium weed. Aylward, Suhrbier, Parsons, Cozzi, Ogbourne. Australian Museum
- 1982: BA Hons. Biochemistry (and honorary MA), New College, University of Oxford, United Kingdom
- 1985: Doctor of Philosophy (Oncology and Cancer Biology), University of Southampton, United Kingdom
You can follow Dr. Suhrbier’s views on biotech in Australia at his Twitter account.